RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
BLOOD
Collezione ASL Biella

Items : 16

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy. in Blood / Blood. 2024 Feb 1;143(5):422-428. doi: 10.1182/blood.2023020984.

2024
ASL Biella

Bommier C; Zucca E; Chevret S; Conconi A; Nowakowski G; Maurer MJ; Cerhan JR; Thieblemont C; Lambert J;

Rituximab and Lenalidomide (R 2) Vs Rituximab Alone As Maintenance Treatment after Chemoimmunotherapy for Elderly Patients with Relapsed/Refractory Follicular Lymphoma (FL): Final Analysis of Renoir Phase III Study of the Fondazione Italiana Linfomi (FIL) in Blood

2023
ASL Biella

Boccomini C; Botto B; Evangelista A; Zilioli VR; Anastasia A; Cavallo F; Merli F; Zanni M; Tani M; Chiarenza A; Liberati AM; Conconi A; Corradini P; Bari A; Annechini G; Gaidano G; Spina M; Sartori R; Castellino C; Puccini B; Arcari A; Bigliardi S; Matta G; Merli M; Mannina D; Marino D; Galieni P; Ciambelli F; Musuraca G; et alii...

Marsun, a Phase III, Multicenter, Open Label, Randomized, Controlled Study Investigating Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients with Relapsed or Refractory Marginal Zone Lymphoma (R/R MZL) in Blood

2023
ASL Biella

Thieblemont C; Conconi A; Buske C; Luminari S; Dreyling M; da Silva MG; Andre M; Flores M; Brahami-Aissou K; Cony-Makhoul P; Carras S;

Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma in Blood

2022
ASL Biella

Bommier C; Conconi A; Zucca E; Nowakowski GS; Cerhan JR; Thieblemont C; Lambert J;

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up in Blood

2022
ASL Biella

Cilloni D; Umurungi J; Bonuomo V; Itri F; Rotolo C; Marini S; Lunghi M; Castelli A; Fava C; Saglio G; Cignetti A; Petiti J;

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) in Blood

2022
ASL Biella
ASL Torino 4

Lanino L; Salutari P; Perego A; Fattizzo B; Riva M; Ubezio M; Musto P; Cilloni D; Oliva EN; Voso MT; Pelizzari AM; Poloni A; Capodanno I; Elena C; Fozza C; Pane F; Breccia M; De Gobbi M; Di Bassiano F; Barraco D; Crisà E; Ferrero D; Frairia C; Vaccarino A; Griguolo D; Paolini S; Quintini M; Sessa M; Turrini M; et alii...

Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study in Blood

2022
ASL Biella

Bosi A; Fattizzo B; Rizzo L; Ferrari S; Lussana F; Borin LM; Castelli A; Bianchi P; Barcellini W; Cairoli R; Molteni A; Riva M;

Clinical relevance of clonal hematopoiesis in persons aged ?80 years. in Blood / Blood. 2021 Nov 25;138(21):2093-2105. doi: 10.1182/blood.2021011320.

2021
ASL Biella

Della Porta MG; Kern W; Lucca U; Haferlach T; Vassiliou GS; Castellani G; Bolli N; Sole F; Fenaux P; Platzbecker U; Santoro A; Passamonti F; Riva E; Condorelli G; Saitta C; Rosso S; Zanetti R; Sala L; Detoma P; Malabaila A; Termanini A; Giordano L; Sala C; Corrao G; Piazza R; Civilini E; Allavena P; Russo A; Tentori CA; et alii...

Clinical relevance of clonal hematopoiesis in persons aged ?80 years in Blood

2021
ASL Biella

Rossi M; Meggendorfer M; Zampini M; Tettamanti M; Riva E; Travaglino E; Bersanelli M; Mandelli S; Antonella Galbussera A; Mosca E; Saba E; Chiereghin C; Manes N; Milanesi C; Ubezio M; Morabito L; Peano C; Soldà G; Asselta R; Duga S; Selmi C; De Santis M; Malik K; Maggioni G; Bicchieri M; Campagna A; Tentori CA; Russo A; Civilini E; et alii...

Clinical relevance of clonal hematopoiesis in persons aged ?80 years in Blood

2021
ASL Biella

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Benevolo G; Ferrero S; Villivà N; Castiglione A; Monaco F; Boccomini C; Cabras MG; Califano C; Casula P; Cavallo F; Conconi A; Drandi D; Gaidano G; Gregorini AI; Felici S; Ferrante M; Mannina D; Molinari AL; Musto P; Musuraca G; Merli M; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Luminari S; Nizzoli ME; Chiarenza A; Mannina D; Tucci A; Boccomini C; Farina L; Olivieri J; Marcheselli L; Ferrero S; Arcaini L; Pulsoni A; Musuraca G; Califano C; Merli M; Bari A; Conconi A; Re F; Balzarotti M; Ladetto M; Patti C; Pinto A; Cabras MG; Musto P; Gini G; Arcari A; Manni M; Versari A; Federico M; et alii...

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. in Blood / Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958. Epub 2018 May 2.

2018
ASL Biella

Cozens K; Porro E; Giovanella L; Bellei M; Cavalli F; Conconi A; Stathis A; Di Rocco A; Zinzani PL; Cascione L; Ferreri AJM; Martelli M; Zucca E; Johnson PW; Milan L; Ceriani L;

Clinical and molecular results of the phase II BRB (bendamustine, rituximab and bortezomib) trial of the fondazione italiana linfomi (FIL) for relapsed/refractory waldenström macroglobulinemia patients in Blood

2018
ASL Biella
AOU Città della Salute di Torino

Benevolo G; Ferrero S; Andriani A; Castiglione A; Baraldi A; Boccomini C; Cabras MG; Califano C; Cavallo F; Conconi A; Curreli L; Drandi D; Gaidano G; Felici S; Ferrante M; Mannina D; Merli M; Molinari AL; Musto P; Musuraca G; Rossi FG; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

A MALT lymphoma prognostic index. in Blood / Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915. Epub 2017 Jul 18.

2017
ASL Biella

Zucca E; Torri V; Cavalli F; Johnson PW; Lopez Guillermo A; Coiffier B; Laszlo D; Martelli M; Gaidano G; Kiesewetter B; Raderer M; Conconi A; Cascione L; Thieblemont C;

IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) in Blood

2017
ASL Biella

Luminari S; Cavalli F; Zucca E; Thieblemont C; Molinari AL; Pulsoni A; Ielmini N; Cabras MG; Capochiani E; Califano C; Tilly H; Salvi F; Conconi A; Palombi F; Cavallo F; Gouill SL; Gini G; Ferrari A; Gyan E; Morschhauser F; Coiffier B; Musuraca G; Guieze R; Marino D; Stathis A; Gregorini A; Gressin R; Orsucci L; Perrot A; et alii...